Albumin for Hepatocellular Carcinoma
Hepatocellular Carcinoma, Hypoproteinemia
About this trial
This is an interventional treatment trial for Hepatocellular Carcinoma
Eligibility Criteria
Inclusion Criteria:
- Body mass index >18.5;
- Patients with primary hepatocellular carcinoma without any treatments for tumors before resection;
- Hepatocellular carcinoma should be confirmed by histopathology;
- With preserved liver function (Child-Pugh score ≤7) before resection
- ECOG performance score 0 or 1;
- Preoperative serum albumin >35g/L;
- The level of postoperative serum albumin is between 25-30g/L in the first day after resection.
Exclusion Criteria:
- Patients used albumin before liver resection (<1 months);
- Plasma was used during or after liver resection;
- Surgery involving the extrahepatic bile duct or gastrointestinal tract.
Sites / Locations
- Affiliated Tumor Hospital of Guangxi Medical UniversityRecruiting
- Jian-Hong Zhong
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Albumin infusion group
Empty control
Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after hepatic resection in 24 h for three days. All patients wil receive furosemide (10 mg, iv) after albumin transfusion. In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
Conventional liver protection and rehydration therapy.In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).